Who are NBP607-TIV's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tat, HD Vaccine, Mycobacterium Vaccae for Injection, TEP, Hepavax-Gene, NASVAC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nbp607-tiv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

NBP607-TIV — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NBP607-TIV (NBP607-TIV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Therapeutic vaccine. Area: Immunology / Infectious Disease.

phase 3 Therapeutic vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

NBP607-TIV (NBP607-TIV) — SK Chemicals Co., Ltd.. NBP607-TIV is a therapeutic influenza vaccine designed to enhance immune response against multiple influenza virus strains.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NBP607-TIV TARGET	NBP607-TIV	SK Chemicals Co., Ltd.	phase 3	Therapeutic vaccine
Tat	Tat	Barbara Ensoli, MD	marketed	Therapeutic vaccine	HIV Tat protein
HD Vaccine	HD Vaccine	Insight Therapeutics, LLC	marketed	Therapeutic vaccine	Huntingtin protein (HTT)
Mycobacterium Vaccae for Injection	Mycobacterium Vaccae for Injection	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.	marketed	Immunotherapeutic vaccine
TEP	TEP	Immungenetics AG	marketed	Therapeutic vaccine
Hepavax-Gene	Hepavax-Gene	Chiang Mai University	phase 3	Therapeutic vaccine	Hepatitis B virus antigens
NASVAC	NASVAC	Clinical Research Organization, Dhaka, Bangladesh	phase 3	Therapeutic vaccine	Hepatitis B surface antigen (HBsAg)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Therapeutic vaccine class)

Immunitor LLC · 3 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Henogen · 2 drugs in this class
SK Chemicals Co., Ltd. · 2 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class
Cytos Biotechnology AG · 2 drugs in this class
Clinical Research Organization, Dhaka, Bangladesh · 1 drug in this class
Barbara Ensoli, MD · 1 drug in this class
Green Cross Corporation · 1 drug in this class
Chiang Mai University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NBP607-TIV — Competitive Intelligence Brief. https://druglandscape.com/ci/nbp607-tiv. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing